Pharma IT
Where data integrity, automation and AI actually meet the plant floor.
ArticleCan AI Decode the Gut? : Machine Learning in Microbiome Research
AI is decoding microbial patterns humans can't see. Here's how machine learning is transforming microbiome research into clinical reality.
How ML Virtual Screening Is Scaling Cancer Drug Targets?
ML virtual screening hits 18-45% in prospective trials vs sub-1% for HTS, unlocking undruggable cancer targets.
Schrodinger vs. Insilico Medicine: A Comparison Report
Physics vs generative AI for cancer drug design. Schrodinger and Insilico Medicine compared pipeline, deals, and proof.
The Top AI Chemistry Platforms Transforming Small Molecule Oncology in 2026
Fewer than 700 of 20,000 human proteins have ever yielded a drug. 5 AI platforms are unlocking oncology's "undruggable" targets.
Quantifying the ROI: Do AI Chemistry Platforms Actually Reduce Pharma R&D Costs?
AI drug discovery raised billions in deals. Deloitte's 2026 report found the ROI "hasn't been realized at scale" yet. Here's why.
8 Things to Know About Rasayan Labs, the Startup Building an AI Operating System for Drug Discovery
Discover how Rasayan Labs accelerates drug discovery with an AI platform for retrosynthesis, ADMET, patents, and compound research.
The Patent Problem: Who Really Owns What AI Discovers in Science?
AI is discovering drugs but cannot own a patent. Explore who holds IP rights in AI-assisted pharma discovery and what your team must do.
When AI Gets It Wrong: The Real Patient Safety Risk of AI Hallucinations in Healthcare
AI hallucinations in pharma are a real patient safety risk. Wrong doses, false data, missed signals here's what governance looks like.
Is Pharma's AI Investment Actually Paying Off? Here's What the Numbers Say
Pharma AI ROI, pharmacovigilance and manufacturing deliver 1-3 year returns. Drug discovery takes 7-12 years. Real data, honest measurement framework.
How AI Is Changing the Way Pharma Research Teams Work
AI is reshaping pharma research teams, faster drug discovery, smarter decisions, and real results from companies already leading the shift.
